background
extracellular
cyclophilin
ecyp
proinflammatori
factor
implic
pathogenesi
number
inflammatori
diseas
pathogen
activ
ecyp
relat
chemotact
action
toward
leukocyt
mediat
ecyp
receptor
target
cell
involv
peptidylprolyl
cistran
isomeras
activ
cyclophilin
activ
inhibit
cyclosporin
csa
nonimmunosuppress
deriv
drug
accumul
evid
role
ecyp
diseas
pathogenesi
stimul
research
mechan
ecypiniti
event
result
identif
multipl
signal
pathway
character
varieti
effector
molecul
releas
ecyptr
cell
synthesi
csa
deriv
specif
block
ecyp
howev
number
import
question
relat
mode
action
ecyp
remain
unansw
scope
review
articl
integr
avail
inform
releas
function
extracellular
cyclophilin
unifi
model
focus
outstand
issu
need
clarifi
major
conclus
extracellular
cyclophilin
critic
player
pathogenesi
number
inflammatori
diseas
mechan
action
involv
interact
receptor
initi
poorli
character
signal
transduct
process
culmin
chemotaxi
product
proinflammatori
factor
gener
signific
extracellular
cyclophilin
present
attract
target
therapeut
intervent
use
allevi
symptom
consequ
acut
chronic
inflamm
articl
part
special
issu
entitl
prolinedirect
foldas
cell
signal
catalyst
drug
target
cyclophilin
ubiquit
express
intracellular
protein
first
recogn
host
cell
receptor
potent
immunosuppress
drug
cyclosporin
later
establish
cyclophilin
previous
identifi
peptidylprolyl
isomeras
character
abil
catalyz
interconvers
ci
tran
isom
prolin
protein
famili
human
cyclophilin
includ
seventeen
identifi
member
cyclophilin
highli
abund
protein
exampl
cypa
present
cell
micromolar
concentr
local
varieti
cellular
organel
subcellular
compart
suggest
may
perform
import
cellular
function
therefor
surpris
knockout
cypa
impact
cell
viabil
life
span
knock
anim
intracellular
function
case
relat
isomeras
activ
character
small
number
cyclophilin
see
recent
review
hoffmann
schienefisch
defici
due
limit
knowledg
protein
interact
cyclophilin
mostli
transitori
natur
interact
characterist
enzymat
reaction
interestingli
sever
member
human
cyclophilin
famili
cyclophilinlik
protein
found
lack
isomeras
activ
bind
csa
probabl
reflect
redund
within
famili
molecul
long
evolutionari
histori
first
cyclophilin
found
extracellular
fluid
cyclophilin
b
cypb
abund
protein
local
er
due
ntermin
signal
sequenc
identifi
human
milk
initi
describ
secret
protein
later
studi
group
suggest
secret
cypb
ctermin
truncat
protein
lack
portion
unconvent
ctermin
er
retent
signal
howev
proteas
respons
cleavag
mechan
regul
process
physiolog
patholog
condit
report
moreov
recent
report
character
er
retent
signal
cypb
overlap
csabind
site
locat
away
cterminu
demonstr
csa
treatment
mutat
tryptophan
csabind
site
releas
cypb
extracellular
milieu
given
cypb
found
compon
extens
network
er
chaperon
fold
catalyst
includ
bip
cochaperon
member
protein
disulfid
isomeras
pdi
complex
pdi
calnexin
calreticulin
biochimica
biochimica
et
biophysica
acta
j
u
r
n
l
h
e
p
g
e
w
w
w
e
l
e
v
e
r
c
l
c
e
b
b
g
e
n
interact
er
resid
protein
via
csabind
site
may
determin
er
local
cypb
explain
secret
protein
csa
treatment
remain
unclear
secret
cypb
regul
csa
present
surpris
initi
underappreci
find
report
cyclophilin
abund
cytosol
protein
secret
macrophag
respons
lp
stimul
mechan
cypa
secret
remain
mysteri
long
time
protein
lack
known
export
signal
later
studi
demonstr
cypa
secret
regul
vesicular
mechan
depend
rho
activ
consist
previou
report
cypa
releas
cell
subject
differ
type
stress
recent
proteom
analysi
cypa
releas
irradi
breast
cancer
cell
suggest
posttransl
modif
secret
cyclophilin
find
confirm
studi
perform
smooth
muscl
cell
treat
oxid
stressinduc
agent
angiotensin
ii
specif
acetyl
lysin
residu
found
necessari
secret
activ
cypa
endotheli
cell
consist
previou
studi
show
rhodepend
secret
cypa
acetyl
cypa
also
depend
rho
support
essenti
role
acetyl
process
cypa
secret
least
case
smooth
muscl
cell
subject
oxid
stress
remain
determin
widespread
pattern
secret
whether
involv
secret
cyclophilin
cypb
cypc
given
constitut
secret
cypa
cypb
describ
certain
cell
type
cypa
secret
fibroblastlik
synoviocyt
head
neckor
squamou
carcinoma
cell
adipocyt
differenti
cypb
secret
chondrocyt
pancreat
cancer
cell
also
import
determin
ratio
acetyl
nonacetyl
cyclophilin
particular
cypa
variou
cell
type
variou
activ
stimuli
inde
acetyl
mark
cypa
molecul
destin
secret
knowledg
proport
molecul
whole
pool
intracellular
cypa
particular
cell
type
specif
treatment
condit
activ
infect
etc
would
provid
estim
potenti
contribut
cell
inflammatori
respons
may
identifi
target
therapeut
intervent
third
member
cyclophilin
famili
secret
cell
cypc
secret
protein
detect
proteom
approach
preadipocyt
undergo
differenti
adipocyt
unstimul
rat
leptomening
cell
recent
studi
demonstr
similar
cypb
cypc
local
er
releas
extracellular
space
csa
treatment
remain
determin
whether
extracellular
cypc
play
specif
physiolog
patholog
role
initi
studi
focus
intracellular
activ
cyclophilin
accumul
evid
suggest
role
protein
mediat
intercellular
commun
two
excel
recent
review
provid
comprehens
descript
extracellular
cyclophilin
function
activ
articl
attempt
integr
avail
inform
medic
import
molecul
unifi
model
focus
unresolv
issu
controversi
remain
field
tabl
secret
cyclophilin
identifi
stimul
proinflammatori
oxid
agent
proteom
approach
includ
function
analysi
therefor
littl
experiment
inform
avail
regard
physiolog
role
extracellular
cyclophilin
issu
remain
open
specul
conjectur
regard
potenti
function
extracellular
cyclophilin
made
studi
perform
knockout
mice
although
model
allow
definit
discrimin
effect
intracellular
extracellular
cyclophilin
initi
analysi
cypa
knockout
mice
reveal
major
defect
life
span
anim
wildtyp
litterm
lead
conclus
cypa
essenti
mammal
result
quit
surpris
given
high
level
express
cypa
tissu
suggest
role
cypa
includ
extracellular
tabl
main
unresolv
issu
relat
extracellular
cyclophilin
known
unknown
refer
receptor
ecyp
essenti
known
effect
ecyp
cypa
catalyz
cistran
isomer
trp
pro
bond
interact
signal
transduc
receptor
integrin
altern
receptor
ecyp
differ
ecypa
ecypb
interact
isomer
respons
signal
transduct
signal
gener
molecul
involv
signal
transduct
initi
ecyp
signal
induc
ecyp
ecyp
initi
ca
flux
jnk
activ
signal
transduct
pathway
activ
ecyp
differ
signal
initi
ecypa
ecypb
ecypc
posttransl
modif
ecyp
acetyl
cypa
promot
secret
function
activ
endotheli
cell
acetyl
posttransl
modif
necessari
secret
ecyp
cell
type
ratio
modifi
unmodifi
cyclophilin
variou
cell
type
posttransl
modif
alter
interact
function
activ
ecyp
mechan
ecyp
secret
cypa
secret
via
vesicular
mechan
depend
rho
activ
secret
ecyp
regul
mechan
secret
ecypb
ecypc
function
activ
ecyp
ecypa
chemotact
agent
leukocyt
ecypb
stimul
adhes
memori
cell
extracellular
matrix
ecypa
stimul
product
ro
vsmc
mmp
proinflammatori
cytokin
myeloid
cell
physiolog
function
ecyp
role
ecyp
patholog
inflammatori
diseas
ecyp
therapeut
target
blockad
ecyp
amelior
inflamm
diseas
model
rheumatoid
arthriti
asthma
biliari
atresia
atherosclerosi
reduc
cypa
mice
diseas
treat
target
ecyp
treatment
target
ecyp
compar
current
use
treatment
inflammatori
diseas
eg
nonperm
csa
deriv
extend
halflif
time
creat
pool
molecul
focus
respons
injuri
infect
main
defici
note
cypa
mice
allerg
patholog
associ
increas
product
splenomegali
overexpress
cytokin
defect
link
elimin
modulatori
effect
cypa
nonreceptor
tyrosin
kinas
itk
activ
perform
intracellular
cyclophilin
molecul
contrast
activ
associ
extracellular
cyclophilin
activ
rather
suppress
natur
justifi
design
ecypa
proinflammatori
factor
overal
target
studi
necessari
extract
inform
relat
extracellular
cypa
cypa
knockout
model
conclus
studi
compound
effect
intracellular
cypa
consider
appli
cypb
knockout
mice
show
sever
defect
collagen
glycosyl
collagen
crosslink
fibrillogenesi
contribut
bone
defect
patholog
like
caus
elimin
intracellular
activ
cypb
assist
collagen
fold
lack
extracellular
activ
cypb
may
also
contribut
defect
much
help
respect
knockout
mice
extracellular
cyclophilin
receptor
multipl
defect
lymphocyt
respons
spermatogenesi
retin
neurolog
function
earli
stage
develop
defect
explain
loss
signal
extracellular
cyclophilin
reliabl
conclus
compound
plethora
function
activ
lost
mice
review
proinflammatori
activ
assign
ecypa
extent
ecypb
vitro
studi
review
may
contribut
local
protect
respons
associ
acut
inflamm
damag
consequ
chronic
inflamm
exampl
protect
effect
ecypa
attenu
bloodbrain
barrier
permeabl
tissu
damag
inject
recombin
cypa
stab
wound
model
injuri
chemotact
properti
ecypa
abil
potenti
activ
classic
chemokin
promot
leukocyt
recruit
stimul
product
proinflammatori
cytokin
unpublish
observ
monocyt
cell
provid
plausibl
framework
benefici
activ
ecypa
acut
inflamm
addit
sever
group
report
abil
ecypa
attenu
oxid
stress
prevent
apoptosi
thu
protect
neuron
vascular
smooth
muscl
cell
howev
best
character
damag
effect
ecypa
relat
role
chronic
inflamm
see
side
twofac
natur
ecypa
also
consist
propos
function
ecypa
molecul
relat
damageassoci
molecular
pattern
damp
extracellular
activ
cyclophilin
impli
exist
receptor
target
cell
group
identifi
integr
plasma
membran
glycoprotein
primari
signal
receptor
ecypb
demonstr
necessari
cell
respons
ecypa
case
peptidylprolyl
isomeras
activ
cyclophilin
requir
signal
could
inhibit
csa
receptor
extracellular
cypc
remain
identifi
given
conserv
activ
site
cyclophilin
appear
like
cypc
isomer
use
signal
receptor
use
hela
cell
artifici
modul
express
demonstr
strong
correl
magnitud
chemotact
respons
ecypa
level
express
one
group
report
cypa
mutant
lack
enzymat
activ
preserv
bind
still
induc
strong
chemotaxi
neutrophillik
cell
line
also
describ
three
residu
cypa
arg
thr
mutat
abrog
bind
chemotact
activ
preserv
isomeras
activ
taken
togeth
result
await
confirm
suggest
chemotact
effect
cypa
directli
mediat
via
bind
without
involv
cistran
isomer
mode
action
howev
support
low
affin
interact
absenc
downregul
treatment
ecypa
unpublish
observ
featur
suggest
ecyp
induc
signal
mechan
differ
classic
ligandreceptor
interact
essenti
role
effect
extracellular
cyclophilin
demonstr
mani
studi
review
howev
recent
studi
monocyt
cell
show
induct
ecypa
affect
partial
knockdown
use
shrna
find
await
confirm
suggest
ecypa
may
use
altern
receptor
specif
activ
cell
type
signal
event
exact
mechan
respons
signal
initi
interact
ecypa
remain
poorli
character
earli
studi
suggest
peptid
bond
form
pro
second
extracellular
immunoglobulinlik
domain
target
cypa
cypb
fig
howev
later
analysi
cypa
interact
extracellular
domain
amino
acid
use
advanc
nmr
technolog
demonstr
cypa
catalyz
cistran
isomer
exclus
trp
pro
bond
whether
pro
also
target
cypb
cyclophilin
isomer
differ
bond
remain
determin
latter
possibl
support
differ
cypa
cypb
effect
target
cell
contrast
cypa
shown
stimul
product
proinflammatori
cytokin
monocyt
activ
found
ecypb
also
wherea
ecypb
promot
integrinmedi
adhes
memori
cell
extracellular
matrix
ecypa
exert
activ
fact
inhibit
homotyp
aggreg
cell
ecypainduc
chemotaxi
although
ecypa
promot
adhes
monocyt
extracellular
matrix
differ
effect
cyclophilin
target
receptor
may
also
due
peculiar
interact
target
cell
bind
ecypa
ecypb
cell
depend
heparan
sulfat
proteoglycan
heparinas
treatment
abrog
signal
cyclophilin
requir
heparan
sulfat
like
explain
insuffici
abund
low
affin
interact
upregul
express
activ
cell
remov
heparinas
sensit
ecypainduc
signal
howev
mode
interact
heparan
sulfat
affin
interact
differ
ecypa
ecypb
ecypb
bind
oligosaccharid
via
ntermin
stretch
lysin
lyslysli
wherea
ecypa
reli
purpos
basic
amino
acid
arg
ly
ly
ly
ctermin
part
protein
addit
ecypb
shown
specif
interact
proteoglycan
function
coreceptor
ecypb
wherea
affin
detect
ecypa
unpublish
observ
major
remain
issu
actual
mechan
link
isomer
prolin
bond
extracellular
domain
intracellular
signal
culmin
calcium
flux
activ
signal
event
induc
extracellular
cyclophilin
review
signaltransduc
molecul
shown
associ
cytoplasm
tail
suggest
signal
transduct
may
mediat
interact
involv
extracellular
orand
transmembran
domain
protein
fact
cytoplasm
tail
shown
exert
suppress
rather
stimul
activ
least
nfat
cell
activ
impair
signal
requir
addit
molecul
coreceptor
signal
transduc
entiti
cell
respons
ecypa
illustr
eosinophil
respond
ecypa
despit
express
consist
idea
signal
via
neighbor
molecul
tightli
associ
number
signal
transduc
molecul
integrin
silenc
inhibit
molecul
inhibit
mmp
induct
activ
erk
jnk
interact
may
involv
transmembran
domain
unusu
featur
charg
amino
acid
glu
hydrophob
region
fig
thu
plausibl
mechan
extracellular
cyclophilin
signal
isomer
pro
pro
bond
extracellular
domain
modifi
interact
neighbor
protein
coreceptor
chang
conform
complex
induc
signal
event
origin
coreceptor
remain
determin
protein
interact
fashion
sensit
isomer
prolin
residu
structur
studi
complex
although
highli
challeng
invalu
deciph
mechanist
detail
signal
initi
extracellular
cyclophilin
anoth
import
question
await
resolut
posttransl
modif
extracellular
cyclophilin
recent
report
berk
group
suggest
acetyl
requir
releas
cypa
endotheli
cell
function
activ
smooth
muscl
cell
howev
publish
vitro
studi
describ
activ
ecypa
reli
recombin
cypa
express
escherichia
coli
thu
lack
acetyl
possibl
differ
function
activ
acetyl
nonacetyl
ecypa
quantit
rather
qualit
acetyl
form
effici
induc
respons
howev
also
possibl
acetyl
alter
interact
ecypa
induc
differ
type
signal
respons
increas
level
extracellular
cyclophilin
mostli
ecypa
document
practic
inflammatori
diseas
role
diseas
pathogenesi
verifi
varieti
anim
model
human
diseas
includ
rheumatoid
arthriti
sepsi
asthma
atherosclerosi
number
viral
infect
review
main
mechan
behind
pathogen
effect
extracellular
cyclophilin
chemotact
activ
toward
sever
type
leukocyt
includ
neutrophil
monocyt
lymphocyt
review
attract
excess
number
cell
site
inflamm
exacerb
extend
inflammatori
respons
thu
contribut
convers
acut
inflamm
damag
chronic
respons
respect
interest
follow
kinet
releas
extracellular
cyclophilin
analysi
perform
mous
model
allerg
lung
inflamm
demonstr
level
ecypa
bal
fluid
elev
day
ovalbumin
prime
increas
challeng
day
start
declin
day
despit
daili
challeng
return
normal
level
day
fig
level
ecypb
slightli
elev
day
rose
substanti
day
stay
elev
end
experi
day
inflammatori
respons
measur
number
effectormemori
cell
eosinophil
bal
fluid
lung
tissu
elev
day
day
challeng
reach
steadi
state
day
continu
end
experi
fig
result
suggest
ecypa
contribut
initi
allerg
respons
wherea
ecypb
respons
mainten
inflamm
note
ip
inject
cellperm
nonimmunosuppress
csa
deriv
cellimperm
deriv
day
significantli
reduc
leukocyt
number
lung
tissu
airway
allerg
mice
importantli
bronchial
biopsi
perform
diseas
remiss
human
patient
asthma
show
absenc
classic
leukocyt
chemokin
despit
presenc
persist
proinflammatori
leukocyt
like
ecypb
orand
ecypa
respons
infiltr
cell
persist
inflamm
import
test
presenc
cyclophilin
bronchial
tissu
would
inform
perform
similar
analysi
diseas
model
sampl
obtain
patient
avail
commerci
elisa
kit
discrimin
cypa
cypb
cypc
make
feasibl
measur
level
extracellular
cyclophilin
plasma
tissu
clinic
investig
analysi
would
correl
level
ecyp
diseas
stage
would
provid
time
frame
effect
applic
therapeut
approach
target
ecyp
howev
chemotact
capac
extracellular
cyclophilin
mechan
proinflammatori
activ
extracellular
cypa
shown
upregul
product
proinflammatori
cytokin
monocyt
activ
monocyt
neutrophil
vsmc
secret
thu
contribut
tissu
damag
rheumatoid
arthriti
abdomin
aortic
aneurysm
atherosclerosi
stimul
vsmc
prolifer
intim
thicken
earli
step
atherosclerosi
activ
human
umbil
vein
endotheli
cell
induc
apoptosi
induc
phosphoryl
human
hepat
stellat
cell
promot
liver
fibrosi
mous
model
biliari
atresia
unpublish
result
given
effect
mediat
breadth
may
explain
differ
respons
cell
type
also
suggest
activ
signal
pathway
broad
activ
given
broad
proinflammatori
activ
ecypa
contribut
pathogenesi
larg
number
diseas
target
extracellular
cyclophilin
seem
like
attract
strategi
therapeut
intervent
attract
approach
increas
lack
physiolog
function
extracellular
cyclophilin
known
essenti
health
thu
minim
potenti
advers
effect
treatment
inde
experi
treat
mice
extend
period
time
week
cellimperm
modif
csa
see
neutral
exclus
extracellular
cyclophilin
demonstr
lack
visibl
toxic
unpublish
result
sever
approach
test
neutral
effect
extracellular
cyclophilin
variou
diseas
model
first
one
describ
target
receptor
factor
use
monoclon
antibodi
review
approach
prove
effect
diseas
model
acut
chronic
lung
inflamm
rheumatoid
arthriti
treatment
mice
antibodi
reduc
inflamm
accumul
immun
cell
inflammatori
cytokin
affect
organ
tissu
damag
studi
direct
comparison
treatment
approv
treatment
rheumatoid
arthriti
antibodi
made
report
stronger
antieros
antisynov
effect
antibodi
scid
mice
engraft
human
cartilag
rheumatoid
synovium
tissu
rheumatoid
arthriti
model
comparison
treatment
target
ecyp
receptor
current
use
treatment
need
reproduc
model
rheumatoid
arthriti
eg
collageninduc
arthriti
model
extend
inflammatori
diseas
model
confirm
advantag
target
ecyp
would
justifi
acceler
clinic
develop
promis
therapeut
modal
mous
model
myocardi
infarct
ischemia
reperfus
ir
infarct
size
reduc
mice
treat
antibodi
preserv
left
ventricular
systol
function
damag
control
anim
importantli
addit
protect
effect
antibodi
detect
cypa
knockout
mice
subject
ir
suggest
cypa
act
common
pathway
mediat
ir
injuri
consist
interpret
recruit
monocyt
neutrophil
ir
injuri
inhibit
treatment
magnitud
inhibit
correl
reduct
infarct
size
use
antibodi
antiinflammatori
treatment
attract
proposit
given
avail
technolog
human
murin
monoclon
antibodi
long
halflif
antibodi
blood
anoth
approach
inhibit
ecypinduc
activ
use
antagonist
peptid
deriv
extracellular
domain
acid
peptid
shown
inhibit
mmp
product
invas
synoviocyt
ra
patient
reduc
product
invas
potenti
monocyt
cell
differenti
macrophagelik
cell
pma
treatment
decreas
infect
host
cell
sar
coronaviru
howev
vivo
result
peptid
publish
promis
clinic
perspect
approach
target
extracellular
cyclophilin
small
molecul
drug
specif
bind
inactiv
molecul
feasibl
approach
demonstr
studi
use
nonimmunosuppress
analog
csa
although
drug
target
intracellular
extracellular
cyclophilin
use
proofofprincipl
protect
effect
anticyclophilin
treatment
one
nonimmunosuppress
csa
analog
shown
significantli
diminish
inflamm
mous
model
acut
lung
injuri
prevent
diseas
reactiv
model
chronic
allerg
asthma
reduc
myocardi
fibrosi
coxsackieviru
induc
myocard
mice
prevent
weight
loss
reduc
liver
fibrosi
mous
model
biliari
atresia
unpublish
result
result
support
potenti
applic
nonimmunosuppress
cyclosporin
develop
treatment
hcv
infect
antiinflamm
treatment
modal
howev
abil
drug
inhibit
varieti
intracellular
cyclophilin
mani
exert
physiolog
relev
function
introduc
seriou
caveat
clinic
usag
especi
extend
treatment
time
expect
case
chronic
inflamm
addit
high
intracellular
concentr
cyclophilin
creat
sink
take
ad
drug
circul
signific
advanc
deal
problem
achiev
synthesi
modifi
csa
analog
unabl
enter
cell
thu
inhibit
extracellular
cyclophilin
given
compound
get
cell
use
lower
concentr
nonimmunosuppress
first
exampl
cellimperm
cyclosporin
polyethyleneglycolmodifi
csa
synthes
analog
csa
retain
immunosuppress
function
abil
inhibit
cistran
isomeras
activ
cypa
bulki
peg
group
prevent
compound
enter
cell
compound
shown
partial
inhibit
entri
target
cell
develop
pursu
due
complic
synthesi
procedur
appropri
larg
scale
product
problem
partial
resolv
synthes
drug
contain
dglutam
acid
moieti
carboxytetramethylrhodamin
fluoresc
probe
attach
side
chainmodifi
dser
csa
presenc
fluoresc
probe
allow
clearcut
demonstr
extracellular
local
drug
shown
potent
inhibit
leukocyt
recruit
reduc
airway
mucu
suppress
cytokin
level
improv
lung
function
murin
model
acut
allerg
asthma
importantli
significantli
outperform
activ
recent
cellimperm
benzimidazol
deriv
csa
report
compound
highli
effect
inhibit
recruit
leukocyt
inflamm
mous
model
experiment
induc
periton
delayedtyp
hypersensit
reaction
studi
mous
model
biliari
atresia
demonstr
treatment
cellimperm
csa
prevent
weight
loss
decreas
phosphoryl
reduc
express
fibrosi
mediat
liver
inhibit
develop
liver
fibrosi
unpublish
result
taken
togeth
result
support
great
potenti
therapeut
target
extracellular
cyclophilin
treatment
inflammatori
diseas
studi
discuss
review
provid
framework
evalu
activ
extracellular
cyclophilin
physiolog
pathophysiolog
condit
howev
understand
mechan
action
ecyp
far
complet
sever
import
question
await
resolut
fig
tabl
particular
would
extrem
import
refin
understand
cyclophilininduc
signal
isomer
initi
intracellular
signal
site
besid
involv
signal
respons
ecyp
protein
interact
transduc
signal
respons
ecyp
signal
transduct
pathway
initi
ecyp
posttransl
modif
phosphoryl
acetyl
cyclophilin
affect
secret
abil
interact
induc
signal
answer
relat
question
would
essenti
futur
translat
effort
aim
target
pathway
avail
data
support
view
role
ecyp
promin
enhanc
extend
inflammatori
respons
often
basi
diseas
patholog
diseas
chronic
asthma
extracellular
cyclophilin
appear
primari
chemoattract
inflammatori
cell
therefor
drug
target
ecyp
receptor
potenti
allevi
symptom
mani
diseas
involv
system
local
inflamm
